Literature DB >> 25192965

Characterization of the PLCB1 promoter and regulation by early growth response transcription factor EGR-1.

Stefanie Klenke1, Katharina Rump2, Kai Buschkamp3, Andrea Engler3, Jürgen Peters3, Winfried Siffert4, Ulrich H Frey3.   

Abstract

The Gαq/-Gα11-PLCβ1 pathway is important for intracellular signalling and associated with pathological conditions, such as cardiac hypertrophy. The GNAQ and GNA11 promoters (encoding for Gαq and Gα11) have already been characterized and are both regulated by the transcription factor early growth response 1 (Egr-1). In contrast, the PLCB1 promoter (encoding for the direct downstream effector PLCβ1) has neither been cloned nor characterized. Therefore, the purpose of this study was to 1) characterize the PLCB1 promoter, and 2) assess its potential regulation by Egr-1. By means of 5'- Rapid Amplification of 5'-cDNA ends analysis in human heart tissue we found an initiation of transcription from multiple starting points, the main transcription starting point being located at nt-235 relative to the translation start point. The PLCB1 promoter was cloned and deletion constructs were generated. Luciferase assays were performed in three different cell lines and regulatory regions were identified between nt-595/nt-313 (Hek293: P=0.013; HASMC: P=0.019; H9c2: P=0.005). In electrophoretic mobility shift assays one specific Egr-1 binding site was identified at nt-451/-419 and PLCB1 promoter activity was increased more than 5-fold (Hek293: P=0.0008) and 1,6- fold (H9c2: P=0.0499) following overexpression of Egr-1. Thus, the PLCB1 promoter was characterized for the first time and a specific interaction with the transcription factor Egr-1 was shown. Our data provide a potential molecular mechanism relating to pathophysiological conditions such as cardiac hypertrophy where activation by Egr-1 of Gαq/Gα11-PLCβ1 plays an important role.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Egr-1; Gene expression; Gene regulation; Hypertension; PLCB1; Promoter

Mesh:

Substances:

Year:  2014        PMID: 25192965     DOI: 10.1016/j.ejphar.2014.08.026

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  miR-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase C beta 1.

Authors:  Peng Zhao; Shukai Sun; Yu'e Zhai; Qingwu Tian; Tingting Zhou; Jing Li
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

2.  Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in Kawasaki disease in Han Chinese in Taiwan.

Authors:  Ying-Ju Lin; Jeng-Sheng Chang; Xiang Liu; Hsinyi Tsang; Wen-Kuei Chien; Jin-Hua Chen; Hsin-Yang Hsieh; Kai-Chung Hsueh; Yi-Tzone Shiao; Ju-Pi Li; Cheng-Wen Lin; Chih-Ho Lai; Jer-Yuarn Wu; Chien-Hsiun Chen; Jaung-Geng Lin; Ting-Hsu Lin; Chiu-Chu Liao; Shao-Mei Huang; Yu-Ching Lan; Tsung-Jung Ho; Wen-Miin Liang; Yi-Chun Yeh; Jung-Chun Lin; Fuu-Jen Tsai
Journal:  Sci Rep       Date:  2015-10-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.